- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- Senate passes Drug Quality and Security Act
- Dr. Smith's Diaper Rash Ointment
MORRISTOWN, N.J. — Actavis has launched its version of an epilepsy drug made by UCB.
The generic drug maker said it received approval from the Food and Drug Administration for levetiracetam extended-release tablets and commenced shipping the product following approval. The drug is the generic equivalent of Keppra XR.
U.S. sales of Keppra XR were about $161 million for the 12 months ended June 30, according IMS Health data.